Vaccine, Japanese encephalitis


Generic Medicine Info
Indications and Dosage
Intramuscular
Active immunisation against encephalitis due to Japanese encephalitis virus
Adult: As adsorbed, inactivated virus vaccine: Primary immunisation: 0.5 mL at 0 and 28 days. Alternatively, an accelerated schedule consisting of 0.5 mL at 0 and 7 days may be given when there is insufficient time for the standard course. Primary course should be completed at least 1 week before potential exposure. Booster dose: Given 12-24 months (12 months for those at continued risk) after the primary course.
Child: Primary immunisation: 2 months to <3 years 0.25 mL at 0 and 28 days; ≥3-17 years Same as adult dose. Booster dose: Given 12-24 months (12 months for those at continued risk) after the primary course.

Subcutaneous
Active immunisation against encephalitis due to Japanese encephalitis virus
Adult: As live, attenuated virus vaccine: Primary immunisation: 0.5 mL as single dose. Booster dose: May be given 5 years after the primary dose, in patients at continued risk.
Child: 9 months to 17 years Primary immunisation: 0.5 mL as single dose. Booster dose: Given 12-24 months after the primary dose, in patients at continued risk.
Contraindications
Hypersensitivity. Live, attenuated virus vaccine: Congenital or acquired immunodeficiency (e.g. HIV infection). Pregnancy and lactation (live, attenuated virus vaccine).
Special Precautions
Patients with bleeding disorders (e.g. thrombocytopenia, haemophilia), altered immunocompetence, personal or family history of febrile convulsions. Postpone vaccination in case of acute severe febrile or acute illness. Children. Pregnancy and lactation (adsorbed, inactivated virus vaccine).
Adverse Reactions
Significant: Syncope.
Gastrointestinal disorders: Abdominal pain, diarrhoea, nausea, vomiting.
General disorders and administration site conditions: Fatigue, fever, malaise, irritability; injection site reaction (e.g. tenderness, pain, erythema, swelling, bruising).
Musculoskeletal and connective tissue disorders: Myalgia, arthralgia, chills.
Nervous system disorders: Dizziness, headache.
Respiratory, thoracic and mediastinal disorders: Cough, dyspnoea, nasal congestion, pharyngolaryngeal pain, wheezing.
Skin and subcutaneous tissue disorders: Rash.
Potentially Fatal: Anaphylaxis.
MonitoringParameters
Monitor for anaphylaxis and syncope 15 minutes after administration.
Drug Interactions
Increased risk of bleeding with anticoagulants (IM). Decreased immune response when given with immunosuppressants (e.g. high-dose corticosteroids).
Action
Description: Japanese encephalitis vaccine triggers the immune system to produce neutralising antibodies against Japanese encephalitis virus which correlate with protection and survival.
Onset: 10 days after 1st dose and 28 days after 2nd dose.
Duration: 12-36 months after initiation of the primary course.
Storage
Store between 2-8°C. Do not freeze. Protect from light.
Any unused portions should be disposed in accordance with local requirements.
ATC Classification
J07BA03 - encephalitis, Japanese, live attenuated ; Belongs to the class of encephalitis viral vaccines.
J07BA02 - encephalitis, Japanese, inactivated, whole virus ; Belongs to the class of encephalitis viral vaccines.
References
Anon. Japanese Encephalitis Virus Vaccine (Inactivated). Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 01/08/2018.

Buckingham R (ed). Japanese Encephalitis Vaccines. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 01/08/2018.

IXIARO Inactivated, Adsorbed Injection, Suspension (Valneva Scotland Ltd.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 01/08/2018.

Joint Formulary Committee. Japanese Encephalitis Vaccine. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 01/08/2018.

Disclaimer: This information is independently developed by MIMS based on Vaccine, Japanese encephalitis from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in